Preclinical Evaluation of Combined CP-818 and Doxorubicin for Treatment of Canine Multicentric T Cell Lymphoma

Patient Disease:

Canine T Cell Lymphoma

Study Name:

Preclinical Evaluation of Combined CP-818 and Doxorubicin for Treatment of Canine Multicentric T Cell Lymphoma

Purpose of the study:

  • Evaluate the safety and antitumor activity of a treatment combination given to dogs with multicentric T cell lymphoma

Primary Eligibility Criteria:

  • Dogs with confirmed naïve multicentric T cell lymphoma

  • Must have good function of liver and kidneys, and be free of severe underlying disease

  • Owners must be able to give oral medications twice daily

  • Prior treatment with steroids okay if receiving for less than 2 weeks and with 72-hour washout period

Study Protocol:

  • Determine eligibility: Physical examination, lab work, thoracic radiographs

  • Day 0: Physical exam, study blood collection, lymph node biopsy, administer CPI-818

  • Week 1: Physical examination, lab work, study blood collection, lymph node biopsy, administer doxorubicin + study blood collected for 1 hour post-treatment

  • Week 2: Physical exam, lab work, study blood collection, administer CPI-818 + study blood collected for 4 hour post-treatment

  • Week 3: Physical exam, lab work, study blood collection

  • Weeks 4, 7, 10, & 13: Physical exam, lab work, study blood collection, administer doxorubicin

  • Monthly: Physical exam, lab work, study blood collection

  • CPI-818 given orally continuously through course of study

Owner Responsibilities:

  • To make and keep all appointments for the study protocol

  • Administer oral medications at home

  • Complete daily log to document drug administration and side effects

Financial Incentives:

  • Study will cover all costs related to the study as well as the treatment of any side effects that occur due to the study drug

  • A credit of $1000 will be given upon completion of the study to put towards continued treatment

  • The owner is responsible for costs of tests needed to confirm study eligibility


If you have further questions about any of our clinical trials, please submit an online consulting form. Your consult will then be directed to an appropriate oncology clinician. Requests are typically returned within 5 business days.